Arterial hypertension assessment in a population with chronic myeloid leukemia

Roa-Chamorro, Ricardo; Jaén-Águila, Fernando; Puerta-Puerta, José Manuel; Torres-Quintero, Lucía; González‐Bustos, Pablo; Mediavilla-García, Juan Diego

doi:10.1038/s41598-021-94127-2

Cited by 6 publications

(3 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For those on tyrosine kinase inhibitors, the assessment of blood pressure at every visit (Secondary 5.2) may have a role in recognising the potential implications of this therapy. 15 …”

Section: Resultsmentioning

confidence: 99%

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

Lee

Aktaa

Baker

et al. 2022

European Heart Journal - Quality of Care and Clinical Outcomes

View full text Add to dashboard Cite

Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

show abstract

“…For those on tyrosine kinase inhibitors, the assessment of blood pressure at every visit (Secondary 5.2) may have a role in recognising the potential implications of this therapy. 15 …”

Section: Resultsmentioning

confidence: 99%

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

Lee

Aktaa

Baker

et al. 2022

European Heart Journal - Quality of Care and Clinical Outcomes

View full text Add to dashboard Cite

show abstract

“…However, according to previous studies, it seems that nilotinib is more associated with the development or worsening of arterial hypertension (Roa-Chamorro et al, 2021), as well as coronary disease together with dasatinib (Barber et al, 2017). Nilotinib is especially associated with stroke (Chen et al, 2021), as well as peripheral arterial disease together with dasatinib (Chen et al, 2021).…”

Section: Discussionmentioning

confidence: 98%

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

et al. 2023

View full text Add to dashboard Cite

Introduction: Cardiovascular events are one of the main long-term complications in patients with chronic myeloid leukemia (CML) receiving treatment with tyrosine kinase inhibitors (TKIs). The proper choice of TKI and the adequate management of risk factors may reduce cardiovascular comorbidity in this population.Methods: This study evaluated the cardiovascular risk of a cohort of patients with CML at diagnosis and after follow-up in a specialized cardiovascular risk consultation. In order to do this, we performed data analysis from 35 patients who received TKIs and were referred to the aforementioned consultation between 2015 and 2018 at our center. Cardiovascular risk factors were analyzed separately, as well as integrated into the cardiovascular SCORE, both at diagnosis and at the last visit to the specialized consultation.Results: At the time of diagnosis, 60% had some type of risk factor, 20% had a high or very high risk SCORE, 40% had an intermediate risk, and 40% belonged to the low risk category. During follow-up, the main cardiovascular adverse event observed was hypertension (diagnosed in 8 patients, 23%). 66% of patients quit smoking, achieving control of blood pressure in 95%, diabetes in 50%, weight in 76%, and dyslipidemia in 92%. 5.7% of patients suffered a thrombotic event and a significant percentage of patients showed a reduction in their SCORE.Conclusion: Our study shows the benefit of controlling cardiovascular risk factors through follow-up in a specialized consultation for patients with CML treated with TKI.

show abstract

“…However, edema and fluid retention are reported as more common side effects of BCR-ABL TKIs. Recent evidence suggests that tyrosine kinase has a particular role in cardiovascular calcification, specifically the calcification of heart vessels and valves [ 58 , 59 ].…”

Section: Etiologies Of Cancer Treatment-induced Hypertensionmentioning

confidence: 99%

Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management

Askarinejad,

Alizadehasl,

Jolfayi

et al. 2023

Cardio-Oncology

View full text Add to dashboard Cite

Hypertension is one of the most common comorbidity and the leading cause of cancer-related death in cancer patients. The prevalence of hypertension in cancer patients is much higher than that of the general population. In the older population of cancer patients, specific cancer treatments such as new tyrosine kinase inhibitors and Vascular endothelial growth factor inhibitor drugs give rise to hypertension in cancer patients; The aim of present study is to provide a detailed discussion etiologies of cancer treatment-induced hypertension and explore the most innovative diagnostic and management approaches. This review will address the optimal approach to hypertension treatment, covering treatment initiation thresholds, targets, and the selection of anti-hypertensive agents. The lack of evidence in recent guidelines for managing cardiovascular toxicities in cancer patients can create uncertainty in clinicians' therapeutic and clinical decisions. This review aims to enhance our understanding of hypertension etiology in cancer patients and provide a practical guide to current treatment approaches.

show abstract

Arterial hypertension assessment in a population with chronic myeloid leukemia

Cited by 6 publications

References 49 publications

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management

Contact Info

Product

Resources

About